Main menu
Edison Group
  • Home
  • Sparks
  • Equities

    Equities

    View All Equities

    Equities by Sector

    YXT.com

    MCap

    USD127m

    Last close

    USD23.43

    ▲ 20.23 (632.19%)

    Northern Data Group

    MCap

    EUR486m

    Last close

    EUR7.56

    ▲ 2.33 (44.59%)

    Bodycote

    MCap

    GBP1,572m

    Last close

    GBP9.14

    ▲ −9.00 (−0.98%)

  • Sectors

    Sectors

  • Megatrends

    Megatrends

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

EMIS Group — Internal review uncovers support issue

EMIS Group (AIM: EMIS)

Last close As at 06/08/2026

—

— 0.00 (0.00%)

Market capitalisation

—

More on this equity

Research: TMT

EMIS Group — Internal review uncovers support issue

In an otherwise in-line trading statement, EMIS announced an issue within its customer and product support processes for EMIS Web where it has not been fully meeting the service level and reporting requirements set by NHS Digital in England. This will result in an exceptional charge (our estimate £9m) and potentially higher ongoing costs in the Primary Care business. A 5% reduction in EPS in FY18e and FY19e is more than discounted in the current share price. Further clarity that the scale and cost of this issue are contained should provide support to the share price.

Written by

Katherine Thompson

Director

TMT

EMIS Group

Internal review uncovers support issue

Trading update

Software & comp services

18 January 2018

Price

775p

Market cap

£491m

Net cash (£m) at end FY17

14.0

Shares in issue

63.3m

Free float

98%

Code

EMIS

Primary exchange

AIM

Secondary exchange

N/A

Share price performance

%

1m

3m

12m

Abs

(2.6)

0.8

1.8

Rel (local)

(5.6)

(2.0)

(6.0)

52-week high/low

1,017p

833.5p

Business description

EMIS is a clinical software supplier to the primary care market in the UK (supplying over 50% of UK GP practices), a software supplier to UK pharmacies, and through several acquisitions also supplies specialist and acute care software.

Next events

FY17 results

14 March 2018

Analysts

Katherine Thompson

+44 (0)20 3077 5730

Dan Ridsdale

+44 (0)20 3077 5729

EMIS Group is a research client of Edison Investment Research Limited

In an otherwise in-line trading statement, EMIS announced an issue within its customer and product support processes for EMIS Web where it has not been fully meeting the service level and reporting requirements set by NHS Digital in England. This will result in an exceptional charge (our estimate £9m) and potentially higher ongoing costs in the Primary Care business. A 5% reduction in EPS in FY18e and FY19e is more than discounted in the current share price. Further clarity that the scale and cost of this issue are contained should provide support to the share price.

Year end

Revenue (£m)

PBT*
(£m)

Dil EPS*
(p)

EMIS adj. dil. EPS** (p)

DPS
(p)

P/E
(x)

Yield
(%)

12/16

158.7

39.2

49.4

49.2

23.4

15.7

3.0

12/17e

165.0

37.0

45.7

46.8

25.8

17.0

3.3

12/18e

173.7

38.3

47.1

48.7

26.8

16.4

3.5

12/19e

183.5

43.0

53.0

54.6

27.8

14.6

3.6

Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments. **EMIS adjusted EPS – cash accounts for development costs and excludes exceptional items and amortisation of acquired intangibles.

Reviewing issues with customer & product support

During a review of customer and product support processes, EMIS discovered that some errors in its EMIS Web GP software were a) not being resolved within required timeframes; and b) were not being reported to NHS Digital as required. Management is confident that the errors do not affect patient safety or data, and is working with NHS Digital to ascertain the scale of the issue. While the costs relating to this issue are yet to be finalised, EMIS expects an exceptional charge in the high single-digit millions. On an ongoing basis, we expect that EMIS will need to deploy additional development resource to this area to resolve the error backlog and to deal with new errors in a timely fashion. Management is confident that this will not affect the ongoing EMIS Web procurement in Scotland although, in our view, it may need to provide additional comfort to existing and potential customers that it has adequate internal controls and resources in place to provide good customer support and meet compliance requirements.

Trading update confirms remaining business in line

Aside from the issue above, the company traded in line with expectations in FY17. We have revised our forecasts to reflect a one-off exceptional charge of £9m in FY17 and higher operating costs for the Primary Care business in FY18 and FY19. This reduces our EMIS-adjusted EPS forecasts by 5.0% in FY18 and 4.6% in FY19. We note that net cash at end FY17 of £14.0m was ahead of our £7.2m forecast, providing some element of cushion for the exceptional costs.

Valuation: Reflects uncertainty

The stock is down 20% on the news. On our revised forecasts, this equates to a P/E multiple of 16.4x FY18e and 14.6x FY19e normalised EPS, compared to 19.4x and 17.3x respectively prior to today’s news. On EMIS-adjusted forecasts, the stock is trading at 15.9x FY18e and 14.2x FY19e, which is at a discount to international healthcare software peers and UK software companies.

Review of customer and product support processes

The company has announced that during a review of customer and product support processes, instigated as part of a wider review of the business by the new CEO, it was discovered that the Primary Care business had not been meeting all of its service level requirements and reporting requirements to NHS Digital in respect of EMIS Web. EMIS Web is available for use by English GP practices under the GP Systems of Choice (GPSoC) framework agreement. As part of being selected to be on the GPSoC framework, software suppliers commit to providing certain levels of functionality, certain service level agreements (SLAs) and regular reporting to NHS Digital. This includes regularly reporting software errors/bugs to NHS Digital, classified by order of severity.

Management discovered during the review process that some lower-level errors had not been resolved within the relevant timeframe (ie had not met SLAs) and also had not been reported to NHS Digital. The company is confident that none of these errors relates to patient safety or data (if they were, they would have been classified as a higher-level error) but are mainly linked to the usability of the software. It has been working with NHS Digital to ascertain the full extent of the issue.

Initial estimates are for an exceptional charge in the upper single-digit millions of pounds; the company expects to update the market when it has a more concrete estimate. We expect that this charge would include any penalties payable to NHS Digital for missing SLAs and for not adhering to reporting requirements. In addition, it would include the cost of ascertaining the extent of the problem. We would expect an ongoing cost to the business of fixing the existing backlog of errors as well as fixing newly discovered errors within the SLA time limits. EMIS could deal with this either by redeploying existing developers from other project work, or could hire extra staff to undertake the work. We have taken a prudent approach and assumed a higher ongoing level of operating costs for the Primary, Community & Acute Care division in FY18 and FY19.

FY17 trading update

The company also announced that trading for FY17 was in line with expectations, with revenues slightly above the level in FY16. The internal reorganisation is now complete. On a divisional basis:

■

Primary, Community & Acute Care: Primary care has maintained its market share. The implementation of EMIS Web in Northern Ireland is progressing well and the procurement process for EMIS Web in Scotland is ongoing. In Wales, the company expects an update on the re-procurement process soon. Community grew market share through further contract wins. Acute Care grew in H2, although hospital demand remained subdued.

■

Community Pharmacy: market share has been maintained and the roll-out of ProScript Connect continues on track.

■

Specialist & Care: the division saw revenue growth and a return to profitability in H217 (our forecast was for a small loss).

■

Patient: the Patient.info and Patient Access websites and mobile apps have been refreshed.

Net cash at year-end stood at £14.0m, well ahead of our £7.2m forecast. This should provide some element of cushion in funding the exceptional costs.

Changes to forecasts

We have revised our forecasts to incorporate a one-off charge of £9m in FY17 and higher operating costs of £2m per annum for Primary Care in FY18 (+2.3%) and FY19 (+2.2%). This reduces EMIS-adjusted EPS by 5.0% in FY18 and 4.6% in FY19. We have not updated our net cash forecast for end FY17, in the absence of detail on working capital and profitability. Therefore, we believe our revised net cash forecasts as at the end of FY18 and FY19 are very conservative. We expect more detail on the precise one-off charge and ongoing costs to the business when the company reports FY17 results on 14 March.

Exhibit 1: Changes to forecasts

£000s

FY17e

FY18e

FY19e

Old

New

Change

y-o-y

Old

New

Change

y-o-y

Old

New

Change

y-o-y

Revenues

164,955

164,955

0.0%

3.9%

173,684

173,684

0.0%

5.3%

183,534

183,534

0.0%

5.7%

Normalised operating profit

36,562

36,562

0.0%

-6.0%

39,809

37,790

-5.1%

3.4%

44,451

42,366

-4.7%

12.1%

Reported operating profit

23,844

14,844

-37.7%

-36.9%

32,091

30,072

-6.3%

102.6%

36,733

34,648

-5.7%

15.2%

EMIS adjusted operating profit

37,275

37,275

0.0%

-3.8%

40,814

38,795

-4.9%

4.1%

45,463

43,377

-4.6%

11.8%

Normalised EPS (p)

45.7

45.7

0.0%

-7.6%

49.7

47.1

-5.2%

3.2%

55.6

53.0

-4.8%

12.4%

Reported EPS (p)

29.6

18.2

-38.7%

-40.2%

40.0

37.5

-6.4%

106.1%

46.0

43.3

-5.8%

15.6%

EMIS adjusted EPS (p)

46.8

46.8

0.0%

-4.9%

51.3

48.7

-5.0%

4.1%

57.2

54.6

-4.6%

12.0%

Net cash/(debt)

7,162

7,162

0.0%

N/A

23,929

13,314

-44.4%

85.9%

43,970

31,686

-27.9%

138.0%

Source: Edison Investment Research. Note: EMIS adjusted forecasts – cash accounts for development costs and excludes exceptional items and amortisation of acquired intangibles.


Exhibit 2: Financial summary

£'000s

2014

2015

2016

2017e

2018e

2019e

Year end 31 December

PROFIT & LOSS

Revenue

 

 

137,639

155,898

158,712

164,955

173,684

183,534

Cost of Sales

(12,782)

(12,955)

(14,151)

(15,440)

(17,229)

(18,665)

Gross Profit

124,857

142,943

144,561

149,515

156,455

164,868

EBITDA

 

 

47,645

51,964

52,288

50,275

52,003

56,679

Operating Profit (before amort. of acq. intang, SBP and except.)

34,787

37,123

38,897

36,562

37,790

42,366

EMIS adjusted operating profit

 

 

32,639

36,553

38,753

37,275

38,795

43,377

Amortisation of acquired intangibles

(6,269)

(6,509)

(6,639)

(6,718)

(6,718)

(6,718)

Exceptionals

873

(18,500)

(6,714)

(14,000)

0

0

Share-based payments

(270)

(684)

(473)

(1,000)

(1,000)

(1,000)

Operating Profit

29,121

11,430

25,071

14,844

30,072

34,648

Net Interest

(543)

(449)

(237)

(150)

(50)

0

Profit Before Tax (norm)

 

 

34,206

36,625

39,159

37,012

38,340

42,966

Profit Before Tax (FRS 3)

 

 

28,540

10,932

25,333

15,294

30,622

35,248

Tax

(5,719)

(5,558)

(5,208)

(3,059)

(6,124)

(7,050)

Profit After Tax (norm)

27,617

29,801

32,175

29,610

30,672

34,373

Profit After Tax (FRS3)

22,821

5,374

20,125

12,235

24,498

28,198

Average Number of Shares Outstanding (m)

62.8

62.7

62.8

62.9

62.9

62.9

EPS - normalised & diluted (p)

 

 

42.8

46.0

49.4

45.7

47.1

53.0

EPS - EMIS adjusted & diluted (p)

 

 

39.4

45.1

49.2

46.8

48.7

54.6

EPS - FRS 3 (p)

 

 

35.3

7.2

30.4

18.2

37.5

43.3

Dividend (p)

18.4

21.2

23.4

25.8

26.8

27.8

Gross Margin (%)

90.7%

91.7%

91.1%

90.6%

90.1%

89.8%

EBITDA Margin (%)

34.6%

33.3%

32.9%

30.5%

29.9%

30.9%

Operating Margin (before GW and except.) (%)

25.3%

23.8%

24.5%

22.2%

21.8%

23.1%

BALANCE SHEET

Fixed Assets

 

 

166,415

143,546

133,292

125,361

116,930

108,399

Intangible Assets

139,397

121,383

110,953

102,122

92,991

83,860

Tangible Assets

24,313

22,032

22,187

23,087

23,787

24,387

Other fixed assets

2,705

131

152

152

152

152

Current Assets

 

 

37,221

39,800

46,088

50,103

58,431

79,259

Stocks

1,550

1,206

1,815

1,815

1,815

1,815

Debtors

28,732

33,893

39,970

41,126

43,302

45,758

Cash

6,939

4,701

4,303

7,162

13,314

31,686

Current Liabilities

 

 

(67,665)

(63,819)

(56,158)

(50,925)

(53,518)

(56,445)

Creditors

(54,763)

(51,960)

(51,425)

(50,925)

(53,518)

(56,445)

Short term borrowings

(12,902)

(11,859)

(4,733)

0

0

0

Long Term Liabilities

 

 

(21,063)

(12,481)

(9,080)

(9,080)

(9,080)

(9,080)

Long term borrowings

(5,854)

(1,951)

0

0

0

0

Other long term liabilities

(15,209)

(10,530)

(9,080)

(9,080)

(9,080)

(9,080)

Net Assets

 

 

114,908

107,046

114,142

115,459

112,763

122,134

CASH FLOW

Operating Cash Flow

 

 

44,856

42,711

43,657

43,619

43,421

57,149

Net Interest

(445)

(422)

(324)

(50)

50

100

Tax

(5,247)

(6,896)

(7,655)

(7,402)

(7,668)

(8,593)

Capex

(15,161)

(14,058)

(12,084)

(12,500)

(12,500)

(12,500)

Acquisitions/disposals

(9,959)

(4,587)

(1,790)

0

0

0

Financing

(1,578)

492

881

(500)

(500)

(500)

Dividends

(10,792)

(14,532)

(14,006)

(15,575)

(16,651)

(17,284)

Net Cash Flow

1,674

2,708

8,679

7,592

6,152

18,372

Opening net debt/(cash)

 

 

13,491

11,817

9,109

430

(7,162)

(13,314)

HP finance leases initiated

0

0

0

0

0

0

Other

0

0

0

0

0

0

Closing net debt/(cash)

 

 

11,817

9,109

430

(7,162)

(13,314)

(31,686)

Source: EMIS, Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting. Edison is authorised and regulated by the Financial Conduct Authority. Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Pty Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER
Copyright 2018 Edison Investment Research Limited. All rights reserved. This report has been commissioned by EMIS Group and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Investment Research Pty Ltd (Corporate Authorised Representative (1252501) of Myonlineadvisers Pty Ltd (AFSL: 427484)) and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited (“FTSE”) © FTSE 2018. “FTSE®” is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE’s express written consent.

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

295 Madison Avenue, 18th Floor

10017, New York

US

Sydney +61 (0)2 8249 8342

Level 12, Office 1205

95 Pitt Street, Sydney

NSW 2000, Australia

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

295 Madison Avenue, 18th Floor

10017, New York

US

Sydney +61 (0)2 8249 8342

Level 12, Office 1205

95 Pitt Street, Sydney

NSW 2000, Australia

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting. Edison is authorised and regulated by the Financial Conduct Authority. Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Pty Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER
Copyright 2018 Edison Investment Research Limited. All rights reserved. This report has been commissioned by EMIS Group and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Investment Research Pty Ltd (Corporate Authorised Representative (1252501) of Myonlineadvisers Pty Ltd (AFSL: 427484)) and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited (“FTSE”) © FTSE 2018. “FTSE®” is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE’s express written consent.

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

295 Madison Avenue, 18th Floor

10017, New York

US

Sydney +61 (0)2 8249 8342

Level 12, Office 1205

95 Pitt Street, Sydney

NSW 2000, Australia

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

295 Madison Avenue, 18th Floor

10017, New York

US

Sydney +61 (0)2 8249 8342

Level 12, Office 1205

95 Pitt Street, Sydney

NSW 2000, Australia

More on EMIS Group

View All

TMT

EMIS Group — Final regulatory approval received for takeover

TMT

EMIS Group — H123 on track; 21.3p interim dividend declared

TMT

EMIS Group — CMA provisionally clears takeover of EMIS

TMT

EMIS Group — FY22 results in line

Latest from the TMT sector

View All TMT content

TMT

ZOO Digital — Rebuilt for a market that now pays for speed

TMT

IP Group — Interesting call option on anti-obesity programme

TMT

4imprint Group — Improved trading feeds through to upgrades

TMT

Filtronic — Foundations in place for growth

Chemring — Flight path adjusted

Chemring is making strong progress on many fronts as market dynamics begin to play in its favour. It has re-established its financial footing and is positioned to drive growth organically and with selective M&A. FY18 is likely to be one of consolidation due to the profile of the 40mm ammunition contracts, but earnings growth anticipated in Countermeasures and Sensors offsets a fall in Energetics. The operational excellence programme targets a 300bp improvement on existing product lines by 2022.

Continue Reading
Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.